Please note: This review reflects information we gathered on the date it was researched and may now be out of date. Providers frequently change their pricing, plans, medications, and policies. Any ratings, reviews, and customer feedback are gathered from publicly available online sources and may have since changed or no longer be accurate. Always do your own research and confirm the latest details directly with the provider before making any decision.
Pendulum Review
A supplement called 'GLP-1 Probiotic' from a company that does real science — and that tells you outright it is not a GLP-1 drug. The question is what the specific product can actually show.
Pendulum GLP-1 Probiotic
Probiotic, Not A DrugStart with the good part: the product page states in plain words that “GLP-1 Probiotic does not contain GLP-1 and is not a GLP-1 agonist drug”. Given the name, that is the disclosure that matters most, and plenty of companies would have left it out. Pendulum also has something almost no supplement brand has: a randomised controlled trial published in a real journal.
The three-strain formula contains Akkermansia muciniphila, Clostridium butyricum and Bifidobacterium infantis. Checked on 7 August 2026 it cost $89 a month as a one-off or $64 on subscription, with a three-month supply at $267 or $173. FSA and HSA eligible.
Now read the footnotes, because two things are easy to conflate. Pendulum's published trial — 33% lower post-meal glucose and 0.6% lower A1C at 12 weeks — tested Glucose Control, a different product. And this product's headline, “91% reported reduced food cravings”, is footnoted as a consumer survey of 274 people — self-reported, unblinded, uncontrolled. Honestly labelled, but not clinical evidence.
Affiliate disclosure: GLP1Drugs.org earns a commission if you buy through the links on this page. We read the cited trials rather than the press releases, and separated what the company has proved from what it has surveyed. Verified 7 August 2026.
Visit PendulumOur Top Recommended Provider: CoreAge Rx
After reviewing dozens of GLP-1 telehealth providers, CoreAge Rx is the one we recommend most. CoreAge Rx is one of our partners — read on for why we recommend them:
Flat-Rate Pricing
Same cost at every dose level — no price jumps as you titrate up.
Verified Pharmacies
US-licensed physicians and NABP-verified 503A compounding pharmacies you can trust.
Everything Included
Medication, supplies, free shipping, and ongoing clinical support — no hidden fees.
Active Community of Members
Ask questions, share progress, and get answers from other patients on the same journey — alongside ongoing clinical support from your care team.
274
People In The Survey Behind 91%
0.6%
A1C Drop — Different Product
~2kg
Less Regain, Different Strain
$64
Per Month On Subscription
What The Evidence Does And Does Not Show
Six distinctions worth holding separate before you spend $64 a month.
It Says What It Is Not
The product page states plainly: 'GLP-1 Probiotic does not contain GLP-1 and is not a GLP-1 agonist drug.' That is the disclosure this product name most needs, and the company makes it
The Mechanism Is Real
Butyrate-producing gut bacteria stimulate the body's own GLP-1 secretion through G-protein coupled receptors. This is established biology, not marketing invention
But The Effect Size Is Not Comparable
Semaglutide 2.4mg produced a mean 14.9% body-weight reduction at 68 weeks in STEP 1. Nudging your own GLP-1 output is a different order of magnitude entirely
The Published RCT Is A Different Product
Pendulum's trial in BMJ Open Diabetes Research & Care — 33% lower post-meal glucose AUC and 0.6% lower A1C at 12 weeks — tested Glucose Control, its 5-strain medical food, not the GLP-1 Probiotic
This Product's Evidence Is A Survey
The headline '91% reported reduced food cravings' is footnoted honestly as a consumer survey of 274 people over six weeks. Self-reported, unblinded, no control group
The Akkermansia Trials Used Someone Else's Strain
The Nature Medicine studies used pasteurized A. muciniphila MucT from The Akkermansia Company. Pendulum uses live Akkermansia — the research supports the ingredient class, not this formulation
Which Study Belongs To What
The single most useful thing on this page. These are three different bodies of evidence, and only one of them is about the product being sold here.
| Evidence | What it tested | Result | Applies to this product? |
|---|---|---|---|
| BMJ Open Diab R&C RCT | Pendulum Glucose Control, 5 strains + inulin, in type 2 diabetes, 12 weeks | 33% lower post-meal glucose AUC; 0.6% lower A1C vs placebo | No — different product |
| Nature Medicine 2019 | Pasteurized A. muciniphila, 32 completers, 3 months | Improved insulin sensitivity; weight change not significant | Partly — different preparation |
| Nature Medicine 2026 | Pasteurized MucT for maintenance after 8-week diet, 90 adults, 24 weeks | 1.2kg regain vs 3.2kg placebo (P=0.012); author COI declared | Partly — another company's strain |
| The 91% claim | GLP-1 Probiotic, 274 people, 6 weeks | 91% self-reported fewer cravings — no control group, unblinded | Yes — but it is a survey |
For scale, the comparison this site exists to make: semaglutide 2.4mg produced a mean 14.9% body-weight reduction at 68 weeks in STEP 1, and tirzepatide 15mg 20.9% at 72 weeks in SURMOUNT-1. Nothing in the table above is in that range, and Pendulum does not claim it is. If you are weighing this against starting treatment, read our provider rankings and our side-effects guide first — both are free.
Pros & Cons
Pros
- ✓It states outright that the product 'does not contain GLP-1 and is not a GLP-1 agonist drug' — the single most important disclosure this product could make
- ✓The company has a genuinely published randomised controlled trial in BMJ Open Diabetes Research & Care, which almost no supplement brand can claim
- ✓That trial reported a 33% reduction in post-meal glucose AUC and a 0.6% reduction in A1C against placebo at 12 weeks
- ✓The proposed mechanism — butyrate-producing strains stimulating endogenous GLP-1 secretion — is established biology rather than invention
- ✓Akkermansia muciniphila has real peer-reviewed human trial data behind it, including a 2026 Nature Medicine weight-maintenance study
- ✓The 91% craving figure is footnoted as a consumer survey rather than dressed up as clinical evidence
- ✓FSA and HSA eligible, with the required FDA disclaimer present
- ✓Subscription pricing is a genuine 28-35% below one-time purchase, not a token discount
Cons
- ✕The published RCT is for Glucose Control, a different product; the GLP-1 Probiotic itself has no equivalent trial we could find
- ✕Its headline evidence is a 274-person consumer survey over six weeks — unblinded, self-reported, uncontrolled
- ✕The Akkermansia weight-maintenance trials used pasteurized MucT from another company; Pendulum's live strain is not the same preparation
- ✕Even taken at face value, the Nature Medicine maintenance result was a roughly 2kg difference in regain — useful, but nowhere near medication territory
- ✕Expensive: $89 a month one-time, or $64 on subscription, for a supplement
- ✕'In order to avoid waste, we do not accept returns'
- ✕Refunds are governed by a 'Money Back Guarantee Policy' the refund page cites repeatedly but which we could not locate
- ✕Damaged items must be reported within 14 days of receipt
- ✕Trustpilot holds only 78 reviews, at 4.0 — a thin independent record for a company of this profile
- ✕The product name invites exactly the confusion the disclaimer has to correct
Our Verdict
3.9 / 5 — one of the few supplement companies doing real science, selling a product whose own evidence is a customer survey. Both halves of that are true and the company is honest about both.
We came to a product called 'GLP-1 Probiotic' expecting to have to write a warning, and largely did not. Pendulum states outright that it does not contain GLP-1 and is not a GLP-1 agonist drug. It footnotes its 91% figure as a consumer survey rather than passing it off as a trial. It has an actual randomised controlled trial in BMJ Open Diabetes Research & Care showing a 33% cut in post-meal glucose and a 0.6% drop in A1C — a result most supplement companies could not produce if their existence depended on it. And the mechanism it describes, butyrate-producing strains stimulating your own GLP-1 secretion, is real biology rather than something invented for a landing page.
The care needed is in matching each piece of evidence to the right product. The published trial belongs to Glucose Control, not to this. The Akkermansia trials — including a 2026 Nature Medicine study where supplementation cut post-diet regain from 3.2kg to 1.2kg — used a pasteurized strain from a different company, with authors who declare co-founder and chief medical officer roles there. What supports this specific formulation is 274 people saying they snacked less. That may well be worth $64 a month to you; it is not a clinical claim, and the honest framing is an adjunct at the margins for someone already doing the things that work. Two practical notes: returns are not accepted, and the Money Back Guarantee the refund policy keeps pointing to is a document we could not find — get its terms in writing before you subscribe.
Visit PendulumFrequently Asked Questions
Is this an alternative to Ozempic or Wegovy?
No, and to its considerable credit Pendulum says so itself. The product page states in plain terms: 'GLP-1 Probiotic does not contain GLP-1 and is not a GLP-1 agonist drug.' We want to give full weight to that, because a supplement called 'GLP-1 Probiotic' could very easily be sold on the implication that it substitutes for semaglutide, and this one explicitly refuses to. What it claims instead is support for your body's own GLP-1 signalling — and the underlying mechanism is genuine biology: butyrate-producing gut bacteria bind G-protein coupled receptors that stimulate endogenous GLP-1 release. The gap that matters is magnitude. In STEP 1, semaglutide 2.4mg produced a mean 14.9% body-weight reduction at 68 weeks. A probiotic that modestly increases your own GLP-1 output is not operating in the same range and nobody credible claims it is. Think of it as a possible adjunct, not a replacement, and never stop or delay a prescribed medication in favour of it.
What evidence actually supports this specific product?
A consumer survey — and the company footnotes it honestly, which is more than most manage. The headline on the page is '91% reported reduced food cravings', and the footnote reads: 'Based on a consumer survey of 274 people taking GLP-1 Probiotic for six weeks.' That is self-reported, unblinded and uncontrolled, which means it cannot separate the product's effect from expectation, from the other changes people make when they start a supplement, or from simple regression to the mean. It is a marketing metric, not a clinical finding, and should be read as one. What Pendulum does have is a real randomised controlled trial published in BMJ Open Diabetes Research & Care: multi-site, double-blind, placebo-controlled, in people with type 2 diabetes on diet and exercise with or without metformin, reporting a 33% reduction in post-meal glucose AUC and a 0.6% reduction in A1C against placebo at 12 weeks. That is a genuinely good result for a supplement. But it tested Pendulum Glucose Control, a five-strain formulation with inulin — a different product from the one this page sells.
What about the Akkermansia research?
It is real, it is improving, and it is not quite about this product. Akkermansia muciniphila is one of the better-studied gut organisms in metabolic health. The 2019 proof-of-concept trial in Nature Medicine randomised overweight and obese insulin-resistant volunteers to live or pasteurized A. muciniphila for three months; pasteurized Akkermansia improved insulin sensitivity and lowered circulating insulin and total cholesterol against placebo, while body weight and fat mass trended down without reaching significance — the study was small, 32 completers, and not powered for weight loss. More interesting for readers here is a 2026 controlled randomised trial in Nature Medicine on weight-loss maintenance: 90 adults lost at least 8% of body weight on an eight-week low-energy diet, then took pasteurized A. muciniphila MucT or placebo for 24 weeks. The MucT group regained 1.2kg against 3.2kg on placebo (P = 0.012), with greater net loss from baseline (3.1kg, P = 0.009). Two caveats matter. Several authors have financial ties to The Akkermansia Company, including co-founder and chief medical officer roles, and hold related patent applications. And that research used pasteurized MucT from that company — Pendulum sells live Akkermansia, so the trials support the ingredient class rather than this specific formulation.
Could it help with weight regain after stopping a GLP-1?
It is the most interesting question about this product, and the honest answer is that nobody has tested it. Weight regain after discontinuation is the central unsolved problem in this field — most people regain much of what they lost. The 2026 Nature Medicine trial is genuinely relevant in shape, because it studied exactly that scenario: maintain a diet-induced loss, and see whether Akkermansia reduces regain. It did, by roughly two kilograms over 24 weeks. But the weight in that trial was lost through an eight-week low-energy diet, not through a GLP-1, and the physiology of post-medication regain is not identical. No trial has tested any probiotic for maintaining GLP-1-induced weight loss. So: a plausible hypothesis with adjacent supporting evidence, not a demonstrated benefit. If you are coming off a GLP-1, the interventions with the strongest evidence remain protein intake and resistance training, and a conversation with your prescriber about tapering rather than stopping abruptly.
What does it cost?
Checked on 7 August 2026, the GLP-1 Probiotic was $89 for a one-month supply as a one-time purchase, or $64 on subscription billed monthly — a 28% saving. A three-month supply was $267 one-time or $173 billed every 90 days, a 35% saving, working out at about $58 a month. Elsewhere in the range, Metabolic Daily started at $49 subscribed against $69 one-time, and Glucose Control — the product with the published trial — at $99 against $139. Purchases are FSA and HSA eligible. At $64 to $89 a month this is at the expensive end of supplements, and the case for that price rests on the strain formulation rather than on trial evidence for this particular product. If the published RCT is what persuades you, note that it belongs to Glucose Control, which costs more again.
Can I return it if it does nothing?
Not in the ordinary sense, and the refund terms are harder to pin down than they should be. The published refund policy states directly: 'In order to avoid waste, we do not accept returns.' It then says that if products 'fail to meet your expectations, as outlined in the Money Back Guarantee Policy, you may request a refund... per the requirements outlined in our Money Back Guarantee Policy', and asks you to explain why you were dissatisfied. So a money-back route exists — but the policy governing it is referenced repeatedly and we could not locate the document itself at the obvious addresses. That means we cannot tell you how long the window is, whether an opened container qualifies, or what conditions apply. Separately, damaged or lost shipments are handled properly: damage must be reported within 14 days of receipt with photographs. Before subscribing, ask customer care for the Money Back Guarantee terms in writing and keep the reply.
Is it safe alongside a GLP-1 medication?
For most people probiotics are well tolerated, and the trials discussed above reported no safety concerns, but there are specific reasons to raise it with your clinician rather than just starting. GLP-1 receptor agonists already slow gastric emptying and commonly cause nausea, bloating and altered bowel habit, particularly during dose escalation; adding a probiotic can produce its own transient gas and bloating, and you may not be able to tell which is causing what. More importantly, live-organism supplements are not recommended for people who are significantly immunocompromised, have central venous catheters, or have serious underlying illness, because of a small but documented risk of bacteraemia. Anyone with short bowel syndrome or recent gastrointestinal surgery should also ask first. And if you have type 2 diabetes and take glucose-lowering medication, anything that genuinely affects post-meal glucose is worth mentioning, because it can matter for dosing.
Who should buy it, and who should not?
It suits someone who is already doing the things with the best evidence — adequate protein, resistance training, a prescribed medication if appropriate — and wants to add something at the margins, understands they are buying a probiotic rather than a drug, and can absorb $64 to $89 a month without resenting it. It suits particularly poorly anyone hoping to avoid or postpone a GLP-1 prescription on the strength of the product name, and the company's own disclaimer says as much. Skip it if the budget is tight, because that money buys a lot of protein. And if the published clinical trial is the thing that convinces you, be clear-eyed that the trial belongs to Glucose Control and was run in people with type 2 diabetes, not to this product in people seeking weight loss.
An Adjunct, Not A Substitute
The company says it is not a GLP-1 drug and it is right. If protein, training and the treatment decision are already handled, this is a reasonable thing to add at the margins.
Visit PendulumCompare Other GLP-1 Providers
See how other telehealth providers stack up.
Amazon One Medical
Brand-Name, No CompoundingFDA-approved Wegovy, Zepbound and Foundayo from $149/month cash, $25 with insurance and $50/month for eligible Medicare members — the first mainstream route to approved medication at prices that compete with compounded. We earn no commission from it
Read Review →JumpstartMD
Comprehensive ProgramMedically supervised program with obesity medicine physicians, dietitians, and in-person options
Read Review →Alan Meds
Top RatedAffordable compounded GLP-1s with board-certified physicians and straightforward pricing
Read Review →GoodRx Care
Trusted BrandTelehealth platform from GoodRx with transparent pricing and established trust
Read Review →Henry Meds
Top RatedWell-established telehealth platform with fast physician reviews and competitive pricing
Read Review →Mochi Health
Obesity Medicine SpecialistsBoard-certified obesity medicine specialists with both brand-name and compounded GLP-1 options
Read Review →Medical Disclaimer: This page is informational and is not medical advice. This is a dietary supplement, not a medicine; it is not intended to diagnose, treat, cure or prevent any disease and it is not a substitute for prescribed treatment. Never stop, delay or alter a prescribed medication in favour of a supplement. Live-organism probiotics are generally well tolerated but are not recommended for people who are significantly immunocompromised, have central venous catheters, or have serious underlying illness, because of a small documented risk of bacteraemia; anyone with short bowel syndrome or recent gastrointestinal surgery should seek advice first. Probiotics can cause transient gas and bloating, which may be difficult to distinguish from GLP-1 side effects during dose escalation. If you take glucose-lowering medication, tell your clinician before adding anything that may affect post-meal glucose. Efficacy figures cited are from published trials in specific populations and are not predictions for any individual.
Date reviewed: 7 August 2026. Prices — $89 one-time or $64 subscribed for a one-month supply, $267 or $173 for three months — the three-strain composition, FSA/HSA eligibility, and the quoted statements 'GLP-1 Probiotic does not contain GLP-1 and is not a GLP-1 agonist drug' and the 91% craving figure with its footnote 'Based on a consumer survey of 274 people taking GLP-1 Probiotic for six weeks' were taken from Pendulum's own product page on that date and may change. The randomised controlled trial reporting a 33% reduction in post-meal glucose AUC and a 0.6% reduction in A1C at 12 weeks was published in BMJ Open Diabetes Research & Care and tested Pendulum Glucose Control, a five-strain formulation with inulin, in people with type 2 diabetes — not the GLP-1 Probiotic. The 2019 Nature Medicine proof-of-concept study of pasteurized Akkermansia muciniphila had 32 completers and reported improved insulin sensitivity with non-significant weight change. The 2026 Nature Medicine controlled randomised trial of pasteurized A. muciniphila MucT for weight-loss maintenance enrolled 90 adults and reported regain of 1.2 ± 0.7kg versus 3.2 ± 0.4kg on placebo (P = 0.012) and greater net loss from baseline (3.1 ± 0.7kg, P = 0.009); several authors declare financial ties to The Akkermansia Company including co-founder and chief medical officer roles and related patent applications, and that trial used a pasteurized strain from that company rather than Pendulum's live formulation. STEP 1 and SURMOUNT-1 figures are as published. Pendulum's refund policy states 'In order to avoid waste, we do not accept returns' and refers refunds to a Money Back Guarantee Policy we could not locate; damaged products must be reported within 14 days. Trustpilot showed 4.0 across 78 reviews.
Affiliate Disclosure: This site may receive compensation from affiliate partners. This does not influence our editorial content or review ratings.